Skip to content
Screener

Allogene Therapeutics ALLO Q1 2026 earnings

Reported May 13, 2026 · After market close

EPS-$0.18Beat by $0.01
Revenue estimate$2.2K
EPS estimate-$0.19

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$2.5K
EPS estimate-$0.13

Financials

Q1 2026

Income statement

See full
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$594.82M+87.5%
Enterprise value$635.27M+79.8%

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

FAQ

When did Allogene Therapeutics report Q1 2026 earnings?
Allogene Therapeutics (ALLO) reported Q1 2026 earnings on May 13, 2026 after market close.
What were Allogene Therapeutics's Q1 2026 revenue and EPS?
Allogene Therapeutics reported eps of $-0.18 for Q1 2026.
Did Allogene Therapeutics beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.19 by $0.01.
How did Allogene Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 35.7% from $-0.28.
Where can I find Allogene Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-034583) and the 10-Q periodic report (0001628280-26-034585) directly on SEC EDGAR. The filing index links above go to sec.gov.